SEC Form 4 · accession 0000905148-26-003352
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Magrath
Officer — Chief Executive Officer · Director
Period of report
Jul 23, 2026
Accepted (ET)
Jul 27, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001228627
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 23, 2026 | S | 9,475 | $2.9473 | D | 1,731,869 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
- F2The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $2.9009 to $3.025, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.